JAK2 and leukemia: The fusion protein can be deemed as a truncated form of JAK2 protein with a COOH‐terminal deletion of the pseudokinase and catalytic domains of the JAK2 protein tyrosine kinase, which is unlikely to be the critical pathogenic fusion for leukemia pathogenesis.